Microsatellite instability in the management of colorectal cancer

References

• Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet. Med.11(1), 35–41 (2009).
   PubMed Web of Science ®Google Scholar
• Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology138(6), 2073–2087 (2010).
   PubMed Web of Science ®Google Scholar
• Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Bland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin. Genet.76(1), 1–18 (2006).
   Google Scholar
• Imai K, Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis29(4), 673–680 (2009).
   Google Scholar
• Wang L, Cunningham JM, Winters JL et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res.63(17), 5209–5212 (2003).
   PubMed Web of Science ®Google Scholar
• Svrcek M, El-Bchiri J, Chalastanis A et al. Specific clinical and biological features characterize inflammatory bowel disease associated colorectal cancers showing microsatellite instability. J. Clin. Oncol.25(27), 4231–4238 (2007).
   PubMed Web of Science ®Google Scholar
• Prolla TA, Pang Q, Alani E, Kolodner RD, Liskay RM. MLH1, PMS1, and MSH2 interactions during the initiation of DNA mismatch repair in yeast. Science265(5175), 1091–1093 (1994).
   PubMedGoogle Scholar
• Fishel R, Ewel A, Lee S, Lescoe MK, Griffith J. Binding of mismatched microsatellite DNA sequences by the human MSH2 protein. Science266(5189), 1403–1405 (1994).
   PubMed Web of Science ®Google Scholar
• Kadyrov FA, Dzantiev L, Constantin N, Modrich P. Endonucleolytic function of MutLα in human mismatch repair. Cell126(2), 297–308 (2006).
   PubMed Web of Science ®Google Scholar
• Duval A, Hamelin R. Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res.62(9), 2447–2454 (2002).
   PubMed Web of Science ®Google Scholar
• Markowitz S, Wang J, Myeroff L et al. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science268(5215), 1336–1338 (1995).
   PubMed Web of Science ®Google Scholar
• Rampino N, Yamamoto H, Ionov Y et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science275(5302), 967–969 (1997).
   PubMed Web of Science ®Google Scholar
• Sammalkorpi H, Alhopuro P, Lehtonen R et al. Background mutation frequency in microsatellite-unstable colorectal cancer. Cancer Res.67(12), 5691–5698 (2007).
   PubMedGoogle Scholar
• Boland CR, Thibodeau SN, Hamilton SR et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res.58(22), 5248–5257 (1998).
   PubMed Web of Science ®Google Scholar
• Perucho M. Correspondence re: C.R. Boland et al., A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res.,58: 5248–5257, 1998. Cancer Res.59(1), 249–256 (1999).
   PubMedGoogle Scholar
• Loukola A, Eklin K, Laiho P et al. Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Res.61(11), 4545–4549 (2001).
   PubMed Web of Science ®Google Scholar
• Laiho P, Launonen V, Lahermo P et al. Low-level microsatellite instability in most colorectal carcinomas. Cancer Res.62(4), 1166–1170 (2002).
   PubMed Web of Science ®Google Scholar
• Suraweera N, Duval A, Reperant M et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology123(6), 1804–1811 (2002).
   PubMed Web of Science ®Google Scholar
• Samowitz WS, Slattery ML, Potter JD, Leppert MF. BAT-26 and BAT-40 instability in colorectal adenomas and carcinomas and germline polymorphisms. Am. J. Pathol.154(6), 1637–1641 (1999).
   PubMedGoogle Scholar
• Pyatt R, Chadwick RB, Johnson CK et al. Polymorphic variation at the BAT-25 and BAT-26 loci in individuals of African origin. Implications for microsatellite instability testing. Am. J. Pathol.155(2), 349–353 (1999).
   PubMed Web of Science ®Google Scholar
• Umar A, Boland CR, Terdiman JP et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl Cancer Inst.96(4), 261–268 (2004).
   PubMed Web of Science ®Google Scholar
• Bacher JW, Flanagan LA, Smalley RL et al. Development of a fluorescent multiplex assay for detection of MSI-high tumors. Dis. Markers20(4–5), 237–250 (2004).
   PubMed Web of Science ®Google Scholar
• Xicola RM, Llor X, Pons E et al. Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J. Natl. Cancer Inst.99(3), 244–252 (2007).
   PubMed Web of Science ®Google Scholar
• Malesci A, Laghi L, Bianchi P et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin. Cancer Res.13(13), 3831–3839 (2007).
   PubMed Web of Science ®Google Scholar
• Hatch SB, Lightfoot HM, Garwacki CP et al. Microsatellite instability testing in colorectal carcinoma: choice of markers affects sensitivity of detection of mismatch repair-deficient tumors. Clin. Cancer Res.11(6), 2180–2187 (2005).
   PubMedGoogle Scholar
• Laghi L, Bianchi P, Malesci A. Differences and evolution of the methods for the assessment of microsatellite instability. Oncogene27(49), 6313–6321 (2008).
   PubMedGoogle Scholar
• Findeisen P, Kloor M, Merx S et al. T25 repeat in the 3´ untranslated region of the CASP2 gene: a sensitive and specific marker for microsatellite instability in colorectal cancer. Cancer Res.65(18), 8072–8078 (2005).
   PubMed Web of Science ®Google Scholar
• Bianchi F, Galizia E, Catalani R et al. CAT25 is a mononucleotide marker to identify HNPCC patients. J. Mol. Diagn.11(3), 248–252 (2009).
   PubMed Web of Science ®Google Scholar
• Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: part I. The utility of immunohistochemistry. J. Mol. Diagn.10(4), 293–300 (2008).
   PubMed Web of Science ®Google Scholar
• De Jong AE, Van Puijenbroek M, Hendriks Y et al. Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clin. Cancer Res.10(3), 972–980 (2004).
   PubMed Web of Science ®Google Scholar
• Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet. Med.11(1), 42–65 (2009).
   PubMed Web of Science ®Google Scholar
• Bessa X, Ballesté B, Andreu M et al. A prospective, multicenter, population based study of BRAF mutational analysis for Lynch syndrome screening. Clin. Gastroenterol. Hepatol.6(2), 206–214 (2008).
   PubMed Web of Science ®Google Scholar
• Deng G, Bell I, Crawley S et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin. Cancer Res.10(1), 191–195 (2004).
   PubMed Web of Science ®Google Scholar
• Domingo E, Niessen RC, Oliveira C et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene24(24), 3995–3998 (2005).
   PubMed Web of Science ®Google Scholar
• Vasen HF, Mecklin JP, Khan PM, Lynch HT. The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis. Colon Rectum34(5), 424–425 (1991).
   PubMed Web of Science ®Google Scholar
• Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology116(6), 1453–1456 (1999).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bigas MA, Boland CR, Hamilton SR et al. A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda Guidelines. J. Natl Cancer Inst.89(23), 1758–1762 (1997).
   PubMedGoogle Scholar
• Umar A, Boland CR, Terdiman JP et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl Cancer Inst.96(4), 261–268 (2004).
   PubMed Web of Science ®Google Scholar
• Järvinen HJ, Aarnio M, Mustonen H et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology118(5), 829–834 (2000).
   PubMed Web of Science ®Google Scholar
• Vasen HF, Möslein G, Alonso A et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J. Med. Genet.44(6), 353–362 (2007).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Colorectal Cancer Screening. Version 1.2010. National Comprehensive Cancer Network, Rockledge, PA, USA (2009).
   Google Scholar
• de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis. Colon Rectum45(12), 1588–1594 (2002).
   PubMed Web of Science ®Google Scholar
• Dove-Edwin I, Boks D, Goff S et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer94(6), 1708–1712 (2002).
   PubMedGoogle Scholar
• Rijcken FE, Mourits MJ, Kleibeuker JH, Hollema H, van der Zee AG. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol. Oncol.91(1), 74–80 (2003).
   PubMedGoogle Scholar
• Renkonen-Sinisalo L, Bützow R, Leminen A, Lehtovirta P, Mecklin JP, Järvinen HJ. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int. J. Cancer120(4), 821–824 (2007).
   PubMedGoogle Scholar
• Goecke T, Schulmann K, Engel C et al. Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. J. Clin. Oncol.24(26), 4285–4292 (2006).
   PubMedGoogle Scholar
• Vasen HF, Möslein G, Alonso A et al. Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Fam. Cancer9(2), 109–115 (2010).
   PubMed Web of Science ®Google Scholar
• Lindor NM, Rabe K, Petersen GM et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA293(16), 1979–1985 (2005).
   PubMed Web of Science ®Google Scholar
• Llor X, Pons E, Xicola RM et al. Differential features of colorectal cancers fulfilling Amsterdam criteria without involvement of the mutator pathway. Clin. Cancer Res.11(20), 7304–7310 (2005).
   PubMedGoogle Scholar
• Barnetson RA, Tenesa A, Farrington SM et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N. Engl. J. Med.354, 2751–2763 (2006).
   PubMed Web of Science ®Google Scholar
• Hampel H, Frankel WL, Martin E et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N. Engl. J. Med.352(18), 1851–1860 (2005).
   PubMed Web of Science ®Google Scholar
• Casey G, Lindor NM, Papadopoulos N et al. Conversion analysis for mutation detection in MLH1 and MSH2 in patients with colorectal cancer. JAMA293(7), 799–809 (2005).
   PubMed Web of Science ®Google Scholar
• Pino MS, Mino-Kenudson M, Wildemore BM et al. Deficient DNA mismatch repair is common in Lynch syndrome-associated colorectal adenomas. J. Mol. Diagn.11(3), 238–247 (2009).
   PubMed Web of Science ®Google Scholar
• Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost–effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet. Med.12(2), 93–104 (2010).
   PubMed Web of Science ®Google Scholar
• Chen S, Wang W, Lee S et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA296(12), 1479–1487 (2006).
   PubMed Web of Science ®Google Scholar
• Balmana J, Stockwell DH, Steyerberg EW et al. Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA296(12), 1469–1478 (2006).
   PubMedGoogle Scholar
• Barnetson RA, Tenesa A, Farrington SM et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N. Engl. J. Med.354(26), 2751–2763 (2006).
   PubMed Web of Science ®Google Scholar
• Pouchet CJ, Wong N, Chong G et al. A comparison of models used to predict MLH1, MSH2 and MSH6 mutation carriers. Ann. Oncol.20(4), 681–688 (2009).
   PubMedGoogle Scholar
• Boland CR. Clinical uses of microsatellite instability testing in colorectal cancer: an ongoing challenge. J. Clin. Oncol.25(7), 754–756 (2007).
   PubMedGoogle Scholar
• Gryfe R, Kim H, Hsieh ET et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl. J. Med.342(2), 69–77 (2000).
   PubMed Web of Science ®Google Scholar
• Benatti P, Gafà R, Barana D et al. Microsatellite instability and colorectal cancer prognosis. Clin. Cancer Res.11(23), 8332–8340 (2005).
   PubMed Web of Science ®Google Scholar
• Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol.23(3), 609–618 (2005).
   PubMed Web of Science ®Google Scholar
• Koopman M, Kortman GA, Mekenkamp L et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br. J. Cancer100(2), 266–273 (2009).
   PubMed Web of Science ®Google Scholar
• Braun MS, Richman SD, Quirke P et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J. Clin. Oncol.26(16), 2690–2698 (2008).
   PubMed Web of Science ®Google Scholar
• Jover R, Zapater P, Castells A et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur. J. Cancer.45(3), 365–373 (2009).
   PubMed Web of Science ®Google Scholar
• Kim GP, Colangelo LH, Wieand HS et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J. Clin. Oncol.25(7), 767–772 (2007).
   PubMed Web of Science ®Google Scholar
• Klump B, Nehls O, Okech T et al. Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature. Int. J. Colorectal Dis.19(1), 23–42 (2004).
   PubMedGoogle Scholar
• Schwitalle Y, Kloor M, Eiermann S et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology134(4), 988–997 (2008).
   PubMed Web of Science ®Google Scholar
• Ogino S, Nosho K, Irahara N et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin. Cancer Res.15(20), 6412–6420 (2009).
   PubMed Web of Science ®Google Scholar
• Nosho K, Baba Y, Tanaka N et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J. Pathol.222(4), 350–366 (2010).
   PubMed Web of Science ®Google Scholar
• Pino MS, Kikuchi H, Zeng M et al. Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology138(4), 1406–1417 (2010).
   PubMed Web of Science ®Google Scholar
• Carethers JM, Chauhan DP, Fink D et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology117(1), 123–131 (1999).
   PubMed Web of Science ®Google Scholar
• Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet355(9217), 1745–1750 (2000).
   PubMed Web of Science ®Google Scholar
• Hemminki A, Mecklin JP, Järvinen H, Aaltonen LA, Joensuu H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology119(4), 921–928 (2000).
   PubMed Web of Science ®Google Scholar
• Liang JT, Huang KC, Lai HS et al. High-frequency microsatellite instability predict better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int. J. Cancer.101(6), 519–525 (2002).
   PubMedGoogle Scholar
• Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med.349(3), 247–257 (2003).
   PubMed Web of Science ®Google Scholar
• Storojeva I, Boulay JL, Heinimann K et al. Prognostic and predictive relevance of microsatellite instability in colorectal cancer. Oncol. Rep.14(1), 241–249 (2005).
   PubMed Web of Science ®Google Scholar
• Jover R, Zapater P, Castells A et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut55(6), 848–855 (2006).
   PubMed Web of Science ®Google Scholar
• Lanza G, Gafà R, Santini A, Maestri I, Guerzoni L, Cavazzini L. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J. Clin. Oncol.24(15), 2359–2367 (2006).
   PubMed Web of Science ®Google Scholar
• Lamberti C, Lundin S, Bogdanow M et al. Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer. Int. J. Colorectal Dis.22(2), 145–152 (2007).
   PubMedGoogle Scholar
• Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur. J. Cancer.45(10), 1890–1896 (2009).
   PubMed Web of Science ®Google Scholar
• Bertagnolli MM, Niedzwiecki D, Compton CC et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J. Clin. Oncol.27(11), 1814–1821 (2009).
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Marsoni S, Monges G et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol.28(20), 3219–3226 (2010).
   PubMed Web of Science ®Google Scholar
• Koi M, Umar A, Chauhan DP et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N’-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res.54(16), 4308–4312 (1994).
   PubMed Web of Science ®Google Scholar
• Hawn MT, Umar A, Carethers JM et al. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res.55(17), 3721–3725 (1995).
   PubMed Web of Science ®Google Scholar
• Carethers JM, Hawn MT, Chauhan DP et al. Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N’-nitro-N-nitrosoguanidine. J. Clin. Invest.98(1), 199–206 (1996).
   PubMed Web of Science ®Google Scholar
• Fink D, Nebel S, Aebi S et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res.56(21), 4881–4886 (1996).
   PubMed Web of Science ®Google Scholar
• Aebi S, Fink D, Gordon R et al. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin. Cancer Res.3(10), 1763–1767 (1997).
   PubMed Web of Science ®Google Scholar
• Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res.61(13), 5193–5201 (2001).
   PubMed Web of Science ®Google Scholar
• Meyers M, Wagner MW, Mazurek A, Schmutte C, Fishel R, Boothman DA. DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J. Biol. Chem.280(7), 5516–5526 (2005).
   PubMedGoogle Scholar
• Arnold CN, Goel A, Boland CR. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int. J. Cancer.106(1), 66–73 (2003).
   PubMed Web of Science ®Google Scholar
• Tajima A, Hess MT, Cabrera BL, Kolodner RD, Carethers JM. The mismatch repair complex hMutS α recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology127(6), 1678–1684 (2004).
   PubMedGoogle Scholar
• Vilar E, Scaltriti M, Balmaña J et al. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br. J. Cancer.99(10), 1607–1612 (2008).
   PubMedGoogle Scholar
• Magrini R, Bhonde MR, Hanski ML et al. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int. J. Cancer101(1), 23–31 (2002).
   PubMed Web of Science ®Google Scholar
• Jacob S, Aguado M, Fallik D, Praz F. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res.61(17), 6555–6562 (2001).
   PubMed Web of Science ®Google Scholar
• Rodriguez R, Hansen LT, Phear G et al. Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11. Clin. Cancer. Res.14(17), 5476–5483 (2008).
   PubMedGoogle Scholar
• Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J. Clin. Oncol.25(23), 3456–3461 (2007).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Labianca R, Bodoky G et al. Randomized Phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol.27(19), 3117–3125 (2009).
   PubMed Web of Science ®Google Scholar
• Fallik D, Borrini F, Boige V et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res.63(18), 5738–5744 (2003).
   PubMed Web of Science ®Google Scholar
• Tejpar S, Bosman F, Delorenzi M et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial) [abstract 4001]. J. Clin. Oncol.27(Suppl. 15), S169 (2009).
   Google Scholar
• Quasar Collaborative Group; Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet370(9604), 2020–2029 (2007).
   PubMed Web of Science ®Google Scholar
• André T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol.27(19), 3109–3116 (2009).
   PubMed Web of Science ®Google Scholar
• des Guetz G, Mariani P, Cucherousset J et al. Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer. Anticancer Res.27(4C), 2715–2719 (2007).
   PubMedGoogle Scholar
• Kim ST, Lee J, Park SH et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother. Pharmacol.66(4), 659–667 (2010).
   PubMed Web of Science ®Google Scholar
• Kim ST, Lee J, Park SH et al. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer. Med. Oncol.27(4), 1277–1285 (2010).
   PubMedGoogle Scholar
• Zaanan A, Cuilliere-Dartigues P, Guilloux A et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann. Oncol.21(4), 772–780 (2010).
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer5(9), 689–698 (2005).
   PubMed Web of Science ®Google Scholar
• Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol.26(22), 3785–3790 (2008).
   PubMed Web of Science ®Google Scholar
• Miquel C, Jacob S, Grandjouan S et al. Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability. Oncogene26(40), 5919–5926 (2007).
   PubMedGoogle Scholar
• Vilar Sanchez E, Chow A, Raskin L, Iniesta MD, Mukherjee B, Grube SB. Preclinical testing of the PARP inhibitor ABT-888 in microsatellite instable colorectal cancer. J. Clin. Oncol.27(15 Suppl.), Abstract 11028 (2009).
   Google Scholar
• Vilar E, Mukherjee B, Kuick R et al. Gene expression patterns in mismatch repair-deficient colorectal cancers highlights the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase–AKT–mammalian target of rapamycin pathway. Clin. Cancer Res.15(8), 2829–2839 (2009).
   PubMedGoogle Scholar
• Swanton C, Marani M, Pardo O et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell11(6), 498–512 (2007).
   PubMed Web of Science ®Google Scholar